We are live on ! Find out more
FCMI

Foresite Capital Management IV Portfolio holdings

AUM $237M
1-Year Est. Return 107.53%
This Fund
S&P 500
This Quarter Est. Return
+5.39%
1 Year Est. Return
+107.53%
3 Year Est. Return
+149.4%
5 Year Est. Return
+13.8%
10 Year Est. Return
AUM
$198M
AUM Growth
+$40.5K
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
100%
Holding
5
New
Increased
Reduced
Closed

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PHVS icon
1
Pharvaris
PHVS
$2.28B
$93.3M 47.16%
4,038,842
KURA icon
2
Kura Oncology
KURA
$793M
$39.5M 19.94%
1,849,947
KNTE
3
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$25.7M 13%
9,671,643
SNDX icon
4
Syndax Pharmaceuticals
SNDX
$1.7B
$20.8M 10.52%
875,000
LYEL icon
5
Lyell Immunopharma
LYEL
$318M
$18.6M 9.38%
416,250

Similar funds

Foresite Capital Management IV's Q1 2024 Portfolio in Review

As of Q1 2024, Foresite Capital Management IV held 5 positions worth $198M, up 0.02% from $198M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q1 2024: portfolio turnover was 0%. Foresite Capital Management IV opened no new positions and made no exits, leaving the 5-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Foresite Capital Management IV's ten largest holdings make up 100% of its $198M portfolio in Q1 2024.
  • Foresite Capital Management IV opened 0 new positions and closed 0 in Q1 2024.
  • Foresite Capital Management IV's portfolio value rose 0.02% quarter-over-quarter to $198M.

Based on Foresite Capital Management IV's 13F filing for Q1 2024, filed 15 May 2024.